(Q40129396)

17 September 2017

title

Sex-specific differences in treatment outcomes for patients with HIV and AIDS. (English)

1 reference

17 September 2017

Edward Stenehjem

1

1 reference

17 September 2017

Judith C Shlay

series ordinal

2

1 reference

17 September 2017

publication date

1 February 2008

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

17 September 2017

published in

1 reference

17 September 2017

volume

8

1 reference

17 September 2017

issue

1

1 reference

17 September 2017

page(s)

51-63

1 reference

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Sex differences in HIV-1 viral load and progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

The stigma of being HIV-positive in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Sustained HIV viral suppression following treatment interruption: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Gender differences in survival in an HIV/AIDS cohort from São Paulo, Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Gender differences in factors associated with adherence to antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

The inability to take medications openly at home: does it help explain gender disparities in HAART use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Sex differences in nevirapine rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Antiretroviral pharmacokinetic profile: a review of sex differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Risk factors for lipodystrophy in the CISAI cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

HIV and aging: implications for patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Treatment of HIV infection in the older patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Changing trends in human immunodeficiency virus and acquired immunodeficiency syndrome in the population aged 50 and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Gender Differences in HIV-1 RNA Rebound Attributed to Incomplete Antiretroviral Adherence Among HIV-Infected Patients in a Population-Based Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

Progression to AIDS and Death and Response to HAART in Men and Women from a Multicenter Hospital-Based Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.8.1.51

21 January 2018

Identifiers

DOI

10.1586/14737167.8.1.51

1 reference

release_zwrgdet3ibftvniqo27igwazwy

17 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zwrgdet3ibftvniqo27igwazwy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference